Literature DB >> 17608814

Growth hormone deficiency (GHD) in adult thalassaemic patients.

Massimo Scacchi1, Leila Danesi, Agnese Cattaneo, Elena Valassi, Francesca Pecori Giraldi, Crocetta Argento, Emanuela D'Angelo, Nadia Mirra, Vittorio Carnelli, Laura Zanaboni, Maria Domenica Cappellini, Francesco Cavagnini.   

Abstract

BACKGROUND AND
OBJECTIVE: Short stature and growth hormone deficiency (GHD) are frequent occurrences in thalassaemic children, while data on the prevalence of GHD in adult patients are lacking. Therefore, we elected to study the growth hormone and insulin-like growth factor-I (GH-IGF-I) axis in a large group of adult thalassaemic subjects.
DESIGN: Cross-sectional study on the prevalence of GHD in 94 adult thalassaemic patients (69 with thalassaemia major and 25 with thalassaemia intermedia, 39 men and 55 women, aged 31.5 +/- 6.8 years, on sex steroid replacement when necessary).
METHODS: All patients underwent GHRH (1 microg/kg as an i.v. bolus) plus arginine (0.5 g/kg as a 30 min i.v. infusion) testing. Severe GHD was defined by GH peaks lower than 9 microg/l, whereas partial GHD was defined by GH peaks ranging from 9-16.5 microg/l. Blood samples for IGF-I, ferritin and pseudocholinesterase measurements were collected. Urinary free cortisol (UFC) levels were also assayed.
RESULTS: Severe GHD was demonstrated in 21 of the 94 patients (22.3%), while 18 additional patients (19.1%) displayed partial GHD. GH peaks were positively correlated with IGF-I standard deviation score (SDS) (r = 0.22, P < 0.05), although 1 of the 21 patients with severe GHD showed normal IGF-I SDS values, and 44 of the 55 patients with normal GH reserve displayed low IGF-I SDS. A strong positive correlation (r = 0.48, P < 0.0001) between IGF-I SDS and pseudocholinesterase was identified. No correlations were found between ferritin and UFC levels on the one hand and GH peaks and IGF-I SDS on the other.
CONCLUSION: Findings from this study demonstrate that GHD, either partial or severe, is not a rare occurrence in adult thalassaemic patients. GHD is associated with a higher prevalence of low serum IGF-I levels, recorded also in patients with normal GH secretion. The lack of correlation between ferritin and both GH peaks and IGF-I SDS suggests that mechanisms additional to iron overload, whose relevance cannot however be definitely ruled out, play a role in the pathophysiology of somatotrophin-somatomedin deficiency in this clinical condition. The positive correlation between IGF-I SDS on the one hand and GH peaks and pseudocholinesterase values on the other hand indicates that reduced liver protidosynthetic activity, in addition to somatotrophin secretory status, is a major determinant of the impaired IGF-I production in thalassaemia. Therefore biosynthetic GH replacement therapy in GH-deficient thalassaemic adults is worth considering.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608814     DOI: 10.1111/j.1365-2265.2007.02965.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  Bone disease in adult patients with β-thalassaemia major: a case-control study.

Authors:  Marina Baldini; Stella Forti; Alessandra Orsatti; Fabio Massimo Ulivieri; Lorena Airaghi; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2011-12-17       Impact factor: 3.397

Review 2.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

3.  Prevalence of growth hormone deficiency in adult polytransfused β-thalassemia patients and correlation with transfusional and chelation parameters.

Authors:  M Poggi; C Pascucci; S Monti; P Pugliese; C Lauri; G Amodeo; G Girelli; V Toscano
Journal:  J Endocrinol Invest       Date:  2010-02-15       Impact factor: 4.256

4.  Growth hormone therapy for people with thalassaemia.

Authors:  Chin Fang Ngim; Nai Ming Lai; Janet Yh Hong; Shir Ley Tan; Amutha Ramadas; Premala Muthukumarasamy; Meow-Keong Thong
Journal:  Cochrane Database Syst Rev       Date:  2020-05-28

5.  Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins.

Authors:  Massimo Scacchi; Leila Danesi; Agnese Cattaneo; Giovanna Sciortino; Raffaella Radin; Alberto Giacinto Ambrogio; Giovanni Vitale; Emanuela D'Angelo; Nadia Mirra; Laura Zanaboni; Marica Arvigo; Mara Boschetti; Diego Ferone; Paolo Marzullo; Marina Baldini; Elena Cassinerio; Maria Domenica Cappellini; Luca Persani; Francesco Cavagnini
Journal:  Endocrine       Date:  2016-01-29       Impact factor: 3.633

6.  Thalassaemia and aberrations of growth and puberty.

Authors:  Andreas Kyriakou; Nicos Skordis
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-07-27       Impact factor: 2.576

7.  Thalassemia major: the present and the future.

Authors:  Marina Baldini
Journal:  N Am J Med Sci       Date:  2012-03

8.  Effects of growth hormone therapeutic supplementation on hematopoietic stem/progenitor cells in children with growth hormone deficiency: focus on proliferation and differentiation capabilities.

Authors:  M P Kawa; I Stecewicz; K Piecyk; E Pius-Sadowska; E Paczkowska; D Rogińska; A Sobuś; K Łuczkowska; E Gawrych; E Petriczko; M Walczak; B Machaliński
Journal:  Endocrine       Date:  2015-04-29       Impact factor: 3.633

9.  Insulin-like Growth Factor-1 (IGF-1): Demographic, Clinical and Laboratory Data in 120 Consecutive Adult Patients with Thalassaemia Major.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Giancarlo Candini; Mohamed Yassin; Giuseppe Raiola; Maria Concetta Galati; Rania Elalaily; Heba Elsedfy; Nicos Skordis; Piernicola Garofalo; Salvatore Anastasi; Saveria Campisi; Mehran Karimi; Christos Kattamis; Duran Canatan; Yurdanur Kilinc; Praveen Sobti; Bernadette Fiscina; Mohamed El Kholy
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576

10.  Growth hormone - insulin-like growth factor-I axis and bone mineral density in adults with thalassemia major.

Authors:  Ashraf Soliman; Vincenzo De Sanctis; Mohamed Yassin; Mohamed O Abdelrahman
Journal:  Indian J Endocrinol Metab       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.